Embecta (NASDAQ:EMBC) Announces Earnings Results

Embecta (NASDAQ:EMBC) released its earnings results on Friday. The company reported $0.56 EPS for the quarter, topping analysts’ consensus estimates of $0.27 by $0.29, Zacks reports. Embecta had a negative return on equity of 23.96% and a net margin of 10.73%.The company had revenue of $271.70 million for the quarter, compared to the consensus estimate of $254.53 million. During the same quarter last year, the business posted $1.12 EPS. Embecta’s quarterly revenue was down 8.1% compared to the same quarter last year. Embecta updated its FY 2026 guidance to 1.800-1.900 EPS.

Here are the key takeaways from Embecta’s conference call:

• U.S. revenue fell 24.6% year over year to approximately $121 million, reflecting weaker insulin-pen prescription trends, customer and payer mix pressure, and prior-year one-time benefits. Management said its outlook assumes no further recovery or deterioration in these market factors.
• Third-quarter revenue declined 8.1% year over year to approximately $272 million, although it improved sequentially by roughly $50 million. International revenue rose 11.5% as reported, helping offset continued U.S. weakness and anticipated softness in China.
• Owen Mumford integration is progressing as planned, adding auto-injectors, pharmaceutical services, and medical devices. Embecta sees a roughly $2.4 billion auto-injector market growing at a double-digit rate, though it is not yet providing specific revenue expectations for the Adaptis platform.
• Embecta raised fiscal 2026 adjusted operating margin guidance to 23.5%–24% from 22.25%–23.25% and adjusted EPS guidance to $1.80–$1.90 from $1.55–$1.75, citing cost controls, lower taxes and interest expense, and share repurchases.
• The company generated approximately $41 million in third-quarter free cash flow, repaid $53 million of debt, and expects to repay at least $150 million during fiscal 2026. Management said continued debt reduction will remain the primary capital-allocation priority.

Embecta Stock Up 26.3%

NASDAQ EMBC traded up $0.92 on Friday, hitting $4.42. The stock had a trading volume of 5,586,683 shares, compared to its average volume of 1,179,668. The company’s 50-day moving average is $3.34 and its two-hundred day moving average is $6.66. The stock has a market cap of $262.24 million, a price-to-earnings ratio of 2.33 and a beta of 0.81. Embecta has a one year low of $2.77 and a one year high of $15.55.

Embecta Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 15th. Shareholders of record on Thursday, August 27th will be paid a dividend of $0.01 per share. This represents a $0.04 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date of this dividend is Thursday, August 27th. Embecta’s payout ratio is presently 2.11%.

Wall Street Analyst Weigh In

EMBC has been the topic of several research analyst reports. Bank of America reduced their price objective on Embecta from $11.00 to $3.00 and set an “underperform” rating on the stock in a research note on Monday, May 18th. Wall Street Zen lowered shares of Embecta from a “strong-buy” rating to a “hold” rating in a research note on Saturday, May 9th. Mizuho lowered their price objective on shares of Embecta from $12.00 to $5.00 and set a “neutral” rating for the company in a research report on Wednesday, May 6th. Zacks Research upgraded shares of Embecta from a “strong sell” rating to a “hold” rating in a research note on Friday, July 17th. Finally, BTIG Research downgraded Embecta from a “buy” rating to a “neutral” rating in a research note on Tuesday, May 5th. Three equities research analysts have rated the stock with a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Reduce” and a consensus price target of $11.00.

Key Headlines Impacting Embecta

Here are the key news stories impacting Embecta this week:

• Positive Sentiment: Q3 earnings and revenue beat estimates: Embecta reported adjusted EPS of $0.56, exceeding the $0.27 consensus estimate, while revenue of $271.7 million topped expectations of $254.5 million. Embecta Q3 earnings report
• Positive Sentiment: Full-year EPS outlook raised: Management provided fiscal 2026 EPS guidance of $1.80–$1.90, above the $1.60 analyst consensus, signaling stronger expected profitability despite business pressures. Embecta fiscal 2026 results
• Positive Sentiment: Dividend maintained: Embecta declared a quarterly cash dividend of $0.01 per share, providing a modest continuing shareholder return. Embecta dividend announcement
• Neutral Sentiment: Strategic diversification: Embecta reiterated its plan to expand beyond insulin delivery into a broader medical-supplies business. The strategy could create longer-term growth opportunities, but the release provided limited detail on execution or near-term returns. Embecta company announcement
• Negative Sentiment: Sales remain under pressure: Quarterly revenue fell 8.1% year over year to $271.7 million, and EPS declined from $1.12 in the comparable period. This highlights ongoing weakness in Embecta’s core operations even with the earnings beat. Embecta earnings details
• Negative Sentiment: Securities-fraud lawsuit adds risk: Multiple law firms publicized a class action alleging Embecta and certain executives misrepresented the commercial stability of its insulin pen-needle business. The August 17 lead-plaintiff deadline increases visibility around potential legal costs, damages and reputational risk. Embecta securities-fraud lawsuit notice

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Larson Financial Group LLC lifted its holdings in Embecta by 368.6% in the third quarter. Larson Financial Group LLC now owns 2,001 shares of the company’s stock worth $28,000 after purchasing an additional 1,574 shares during the period. Tower Research Capital LLC TRC raised its position in shares of Embecta by 542.6% during the 2nd quarter. Tower Research Capital LLC TRC now owns 7,371 shares of the company’s stock worth $71,000 after buying an additional 6,224 shares in the last quarter. Wexford Capital LP acquired a new stake in shares of Embecta in the 3rd quarter worth approximately $94,000. Humankind Investments LLC acquired a new stake in shares of Embecta in the 2nd quarter worth approximately $111,000. Finally, iSAM Funds UK Ltd bought a new position in shares of Embecta in the third quarter valued at approximately $115,000. 93.83% of the stock is owned by institutional investors and hedge funds.

About Embecta

Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.